Does pregabalin improve sleep disorders in fibromyalgia?

Poluha, Rodrigo Lorenzi; Grossmann, Eduardo

doi:10.5935/2595-0118.20180031

Cited by 2 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is estimated that updating the FMS classification criteria, as well as the increased acceptance of the diagnosis, may directly influence the increase in the indicated values of prevalence. FMS has its classification criteria established by American College of Rheumatology 11 and these are widely discussed in Brazil in groups of rheumatologists 12 and groups of studies of pain 13 . Most of the cases in this study reported consulting -mainly -rheumatologists, followed by pain specialists.…”

Section: Discussionmentioning

confidence: 99%

The prevalence of fibromyalgia in Brazil – a population-based study with secondary data of the study on chronic pain prevalence in Brazil

Souza¹,

Perissinotti

2018

Brazilian Journal of Pain

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVES: The prevalence of the fibromyalgia syndrome has been estimated in some Brazilian cities and regions, and previous population-based studies investigating this prevalence, as well as the profile of medical consultations are unknown. METHODS: This study used the database constructed by a previous study of authors to identify the prevalence of chronic pain in Brazil. The cases that reported pain for more than 6 months and with a diagnosis of fibromyalgia were selected. The studied descriptive variables were age, intensity and frequency of pain, pain interference in self-care, walking, working, social life, sexual life, sleep quality, if pain causes sadness or depression or influences the emotional aspects. The total sample was evaluated by rheumatologists and pain-expert doctors. RESULTS: Thirteen cases from the initial database were selected since they reported the diagnosis of the prevalence of the fibromyalgia syndrome representing 2% of the initial study population, average age 35.8 years (9.8). The predominance of the fibromyalgia syndrome was in females (n=11). Pain intensity was 7.3 (2.4), the frequency and duration of pain were constant in the majority of the sample (n=9). Most of the cases report a serious pain interference with sleep (n=8), many said that pain interferes with the work (n=5), irritability (5) and finally, some report that pain has a moderate interference in self-care (n=5), walking (n=6), social life (n=6), sexual life (n=5) and causes moderate sadness or depression (n=5). CONCLUSION: The prevalence of the fibromyalgia syndrome was estimated in 2% of the Brazilian population, based on secondary data of a study on chronic pain prevalence in Brazil. The data was collected in 2015-2016. The most reported complaints were intense and daily pain that interferes with sleep. The prevalence of fibromyalgia in Brazil-a population-based study with secondary data of the study on chronic pain prevalence in Brazil A prevalência da fibromialgia no Brasil-estudo de base populacional com dados secundários da pesquisa de prevalência de dor crônica brasileira

show abstract

Section: Discussionmentioning

confidence: 99%

The prevalence of fibromyalgia in Brazil – a population-based study with secondary data of the study on chronic pain prevalence in Brazil

Souza¹,

Perissinotti

2018

Brazilian Journal of Pain

View full text Add to dashboard Cite

show abstract

“…The long-term safety and tolerability of pregabalin have been demonstrated in previous studies 39 . Somnolence, dizziness, dry mouth and peripheral oedema are the most frequent adverse events occurring in patients receiving pregabalin 40 . The meta-analysis by Haeuser et al 36 reported the adverse effects of different doses of pregabalin.…”

Section: Discussionmentioning

confidence: 99%

Pregabalin administration in patients with fibromyalgia: a Bayesian network meta-analysis

Migliorini

Maffulli

Knobe

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Several studies investigated the effectiveness and the safety of different doses of pregabalin in fibromyalgia. However, the optimal protocol remains controversial. A Bayesian network meta-analysis comparing 300, 450, and 600 mg/daily of pregabalin for fibromyalgia was conducted. The literature search was conducted in January 2022. All the double-blind randomised clinical trials comparing two or more dose protocols of pregabalin for fibromyalgia were accessed. Studies enrolling less than 50 patients were not eligible, nor were those with a length of follow-up shorter than eight weeks. The outcomes of interests were: Fibromyalgia Impact Questionnaire (FIQ), sleep quality, and adverse events. The network meta-analyses were performed using the routine for Bayesian hierarchical random-effects model analysis, with log odd ratio (LOR) and standardized mean difference (SMD) effect measure. Data from 4693 patients (mean age 48.5 years) were retrieved. 93.1% (4370 of 4693 patients) were women. The median follow-up was 14.8 weeks. Pregabalin 450 mg/daily resulted in greater reduction in Fibromyalgia Impact Questionnaire (SMD − 1.83). Pregabalin 600 demonstrated the greatest sleep quality (SMD 0.15). Pregabalin 300 mg/daily evidenced the lowest rate of adverse events (LOR 0.12). The dose of pregabalin must be customised according to patients’ characteristics and main symptoms.

show abstract

Does pregabalin improve sleep disorders in fibromyalgia?

Cited by 2 publications

References 38 publications

The prevalence of fibromyalgia in Brazil – a population-based study with secondary data of the study on chronic pain prevalence in Brazil

The prevalence of fibromyalgia in Brazil – a population-based study with secondary data of the study on chronic pain prevalence in Brazil

Pregabalin administration in patients with fibromyalgia: a Bayesian network meta-analysis

Contact Info

Product

Resources

About